logo

Plasma Protease C1-inhibitor Market Size (2024 - 2029)

The Plasma Protease C1-inhibitor Treatment Market is anticipated to expand significantly during the forecast period, driven by the rising prevalence of hereditary angioedema, a serious genetic condition. Factors contributing to this growth include increased research and development investments, the discovery and approval of new inhibitor drugs, and the introduction of innovative therapies aimed at treating hereditary angioedema. These elements collectively influence the market size, reflecting a positive outlook for the industry.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Inhibitors Research Plasma Protease C1-inhibitor Market Market Size

Market Size of Plasma Protease C1-inhibitor Industry

CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Plasma Protease C1-Inhibitor Market Analysis

The Plasma Protease C1-inhibitor Treatment Market is expected to experience a significant growth over the forecast period due to the growing incidence of hereditary angioedema (HAE). Hereditary angioedema is a potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi), the global umbrella organization for the world's HAE patient groups.

Additionally, increasing R&D investments, discovery of inhibitor drugs, increasing product approvals promising pipeline drugs and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.

Plasma Protease C1-Inhibitor Industry Segmentation

As per the scope of the report, plasma protease C1 inhibitor (C1 Inh) is a member of the serpin family of protease inhibitors and related proteins, and its mechanism of action is identical to those of the other protease inhibitor members of the family. SERPING1 forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases which will play a vital role in the regulation of blood coagulation, complement activation, generation of kinins and fibrinolysis. It is also an efficient FXIIa inhibitor. Mutations of the SERPING1 gene is associated with the adult macular degeneration which causes Hereditary Angioedema (HAE).

By Drug Type
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage Form
Lyphophlised
Injectables
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Plasma Protease C1-inhibitor Market Size Summary

The Plasma Protease C1-inhibitor Treatment Market is poised for substantial expansion over the forecast period, driven by the increasing prevalence of hereditary angioedema (HAE), a serious genetic condition. The market's growth is further bolstered by heightened research and development investments, the discovery of new inhibitor drugs, and a promising pipeline of novel therapies and product approvals. The introduction of bradykinin B2 receptor antagonists, such as Icatibant, has been a significant advancement in treating acute HAE episodes, with regulatory approvals enhancing their availability. The market is also witnessing financial backing for clinical developments, as seen with Pharvaris's substantial funding to advance oral B2-receptor antagonists.

North America leads the global Plasma Protease C1-inhibitor market, attributed to the rising incidence of HAE and robust R&D investments. The region benefits from a well-established healthcare infrastructure, a growing number of product approvals, and the presence of major market players offering effective treatment options. The market is characterized by strategic activities such as partnerships, collaborations, and mergers among key players like CSL Behring LLC, Takeda Pharmaceutical Company Limited, and others. These dynamics, coupled with innovative treatment solutions, are expected to drive the market's growth, particularly in the United States, where significant regulatory approvals have been granted for routine prophylaxis therapies.

Explore More

Plasma Protease C1-inhibitor Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Hereditary Angioedema (HAE)

      2. 1.2.2 Increasing Investments in the Research & Development Activities

    3. 1.3 Market Restraints

      1. 1.3.1 High Price of Esoteric Testing Procedures Restricting Market Entry

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Drug Type

      1. 2.1.1 C1-inhibitors

      2. 2.1.2 Kallikrein Inhibitor

      3. 2.1.3 Selective Bradykinin B2 Receptor Antagonist

    2. 2.2 By Dosage Form

      1. 2.2.1 Lyphophlised

      2. 2.2.2 Injectables

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Plasma Protease C1-inhibitor Market Size FAQs

The Plasma Protease C1-inhibitor Market is projected to register a CAGR of 6.90% during the forecast period (2024-2029)

CSL Behring LLC, Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings), Pharming Technologies B.V., KalVista Pharmaceuticals, Inc. and BioCryst Pharmaceuticals are the major companies operating in the Plasma Protease C1-inhibitor Market.

Plasma Protease C1-inhibitor Report Snapshots

Plasma Protease C1-inhibitor Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)